^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    2d
    JAKUVEITE: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (clinicaltrials.gov)
    P3, N=33, Not yet recruiting, University Hospital, Rouen | Trial completion date: Aug 2029 --> Dec 2029 | Trial primary completion date: Aug 2029 --> Dec 2029
    Trial completion date • Trial primary completion date
    6d
    Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo (clinicaltrials.gov)
    P2, N=156, Completed, Minghui Pharmaceutical (Hangzhou) Ltd | Active, not recruiting --> Completed
    Trial completion
    7d
    A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=13, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Trial termination
    |
    Anxu (rovadicitinib)
    7d
    JAKCNIASSILD: A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, China-Japan Friendship Hospital | Not yet recruiting --> Recruiting | Initiation date: Feb 2026 --> May 2026
    Enrollment open • Trial initiation date
    |
    methylprednisolone sodium succinate
    7d
    ODEN: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (clinicaltrials.gov)
    P=N/A, N=102, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    tofacitinib
    7d
    TQ05105-I-01: A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=79, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown status --> Completed | N=50 --> 79
    Trial completion • Enrollment change
    |
    Anxu (rovadicitinib)
    8d
    BIRD: Baricitinib in Patients With Relapsing or naïve Dermatomyositis (clinicaltrials.gov)
    P3, N=62, Recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    8d
    TQ05105-Ⅱ-01: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=107, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    JAK2 (Janus kinase 2)
    |
    hydroxyurea • Anxu (rovadicitinib)
    10d
    CDAK539A12303: A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior treatment with a Janus kinase inhibitor. (2025-523555-66-00)
    P2/3, N=60, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    12d
    JAK Inhibitor-Induced Improvement of IgA Nephropathy in a Patient With Polycythemia Vera: A Case Report. (PubMed, Kidney Med)
    Because corticosteroid therapy was initially avoided due to concern for exacerbating PV, treatment was initiated with a JAK inhibitor, ruxolitinib...Proposed mechanisms include suppression of IL-6/IL-11-driven platelet-derived growth factor production leading to reduced mesangial proliferation, and modulation of aberrant hematopoietic IgA production. This case suggests that JAK inhibition may not only normalize hematopoiesis in PV but also modify glomerular inflammation in IgAN, particularly in patients with hematologic comorbid conditions.
    Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6)
    |
    Jakafi (ruxolitinib)
    14d
    Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study. (PubMed, Blood Adv)
    Immune correlative studies showed that baricitinib induced significant reductions in cytokine-induced signaling (pSTAT) in both CD4+ and CD8+ T cells, and in proinflammatory cytokine secretion. Baricitinib was well tolerated and exhibited a high rate of durable responses in a severely affected cohort of cGVHD patients, warranting further evaluation in earlier line and larger scale studies.
    P1/2 data • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    14d
    Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    Anxu (rovadicitinib)